Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Letters
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-1074 Online ISSN: 1792-1082
Journal Cover
January-2027 Volume 33 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
January-2027 Volume 33 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article Open Access

Feasibility of a targeted protein panel for personalized treatment in advanced adenoid cystic carcinoma: A proof‑of‑concept study 

  • Authors:
    • Rubens Thölken
    • Adrian Von Witzleben
    • Simon Laban
    • Stephanie Ellen Weissinger
    • Thomas K. Hoffmann
    • Patrick J. Schuler
    • Johannes Doescher
  • View Affiliations / Copyright

    Affiliations: Department of Otorhinolaryngology, Head & Neck Surgery, University of Heidelberg, D-69120 Heidelberg, Germany, Department of Otorhinolaryngology, Head & Neck Surgery, University of Ulm, D-89081 Ulm, Germany, Department of Pathology, University of Ulm, D-89081 Ulm, Germany
    Copyright: © Thölken et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Article Number: 4
    |
    Published online on: November 6, 2026
       https://doi.org/10.3892/ol.2026.15939
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:


Abstract

Treatment options for advanced recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC) remain limited, with few effective molecular‑based therapies. Advances in targeted protein panels provide an approach for identifying potentially targetable protein expression patterns and supporting individualized treatment considerations; however, their feasibility and decision‑support potential in R/M ACC remain poorly defined. The present proof‑of‑concept study evaluated the feasibility and decision‑support potential of a predefined immunohistochemistry‑based 11‑protein panel in heavily pretreated patients with R/M ACC. Among 10 patients with advanced R/M ACC, seven underwent tumor profiling using the panel. Potentially actionable targets, including epidermal growth factor receptor (EGFR), MET proto‑oncogene, receptor tyrosine kinase, KIT proto‑oncogene, receptor tyrosine kinase, and platelet‑derived growth factor receptor, were identified in 86% of profiled cases. Based on these findings, panel‑based therapy recommendations were issued for the majority of patients. In one illustrative case, EGFR‑directed therapy with gefitinib was associated with ~3 years of disease stability. In conclusion, these findings support the feasibility of a pragmatic immunohistochemistry‑based approach to inform treatment discussions in advanced R/M ACC. However, the clinical relevance of these findings requires further validation in larger prospective cohorts.
View Figures

Figure 1

Protein panel. Representative
immunohistochemical staining of the 11-protein panel in advanced
ACC. Staining was performed using alkaline phosphatase (red) or
immunoperoxidase (brown) detection systems. Adapted from Doescher
et al (3) with permission;
reproduced in collaboration with the original authors (3,9,25). The
immunohistochemical images were acquired using a 20× objective.
ACC, adenoid cystic carcinoma; ALK, anaplastic lymphoma kinase; AR,
androgen receptor; EGFR, epidermal growth factor receptor; HER2,
human epidermal growth factor receptor 2; KIT, KIT proto-oncogene,
receptor tyrosine kinase; MET, MET proto-oncogene, receptor
tyrosine kinase; PD-L1, programmed death-ligand 1; PDGFR,
platelet-derived growth factor receptor; VEGFR, vascular
endothelial growth factor receptor.

Figure 2

UpSet plot visualizing combinatory
expression of protein panel markers. ALK, anaplastic lymphoma
kinase; AR, androgen receptor; EGFR, epidermal growth factor
receptor; HER2, human epidermal growth factor receptor 2; KIT, KIT
proto-oncogene, receptor tyrosine kinase; MET, MET proto-oncogene,
receptor tyrosine kinase; PD-L1, programmed death-ligand 1; PDGFR,
platelet-derived growth factor receptor; VEGFR, vascular
endothelial growth factor receptor.
View References

1 

Spiro RH, Huvos AG and Strong EW: Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases. Am J Surg. 128:512–520. 1974. View Article : Google Scholar : PubMed/NCBI

2 

Chae YK, Chung SY, Davis AA, Carneiro BA, Chandra S, Kaplan J, Kalyan A and Giles FJ: Adenoid cystic carcinoma: Current therapy and potential therapeutic advances based on genomic profiling. Oncotarget. 6:37117–37134. 2015. View Article : Google Scholar : PubMed/NCBI

3 

Doescher J, Weissinger SE, Schönsteiner SS, Lisson C, Bullinger L, Barth TF, Leithäuser F, Mueller-Richter U, Laban S, Hoffmann TK, et al: Clinical utility of a protein-based oncopanel in patients with end-stage head and neck cancer. Immunotherapy. 11:1193–1203. 2019. View Article : Google Scholar : PubMed/NCBI

4 

Wysocki PT, Izumchenko E, Meir J, Ha PK, Sidransky D and Brait M: Adenoid cystic carcinoma: Emerging role of translocations and gene fusions. Oncotarget. 7:66239–66254. 2016. View Article : Google Scholar : PubMed/NCBI

5 

Pham T, Pereira L, Roth S, Galletta L, Link E, Akhurst T, Solomon B, Michael M, Darcy P, Sampurno S, et al: First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427). Contemp Clin Trials Commun. 16:1004092019. View Article : Google Scholar : PubMed/NCBI

6 

Zupancic M, Näsman A, Friesland S and Dalianis T: Adenoid cystic carcinoma, clinical presentation, current treatment and approaches towards novel therapies. Anticancer Res. 44:1325–1334. 2024. View Article : Google Scholar : PubMed/NCBI

7 

Stenman G, Licitra L, Said-Al-Naief N, van Zante A and Yarbrough W: Adenoid cystic carcinoma. WHO Classification of Head and Neck Tumours. World Health Organization Classification of Tumours. El-Naggar AK, Chan JKC, Grandis JR, Takata T and Slootweg PJ: 4th edition. Vol 9. International Agency for Research on Cancer; Lyon: pp. 164–165. 2017

8 

Ueda K, Murase T, Nagao T, Kusafuka K, Urano M, Yamamoto H, Nakaguro M, Taguchi KI, Masaki A, Hirai H, et al: Central pathology review of salivary gland adenoid cystic carcinoma. Head Neck. 42:1721–1727. 2020. View Article : Google Scholar : PubMed/NCBI

9 

Grünmüller L, Thierauf J, Weissinger SE, Bergmann C, Bankfalvi A, Veit J, Hoffmann TK, Möller P and Lennerz JK: Biopanel identifies expression status of targetable proteins in sinonasal melanoma. Per Med. 13:291–301. 2016. View Article : Google Scholar : PubMed/NCBI

10 

Gu Z, Eils R and Schlesner M: Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 32:2847–2849. 2016. View Article : Google Scholar : PubMed/NCBI

11 

Zhang J, Peng B and Chen X: Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. Clin Cancer Res. 11:7334–7343. 2005. View Article : Google Scholar : PubMed/NCBI

12 

Locati LD, Cavalieri S, Bergamini C, Resteghini C, Alfieri S, Calareso G, Bossi P, Perrone F, Tamborini E, Quattrone P, et al: Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract. Head Neck. 41:3670–3676. 2019. View Article : Google Scholar : PubMed/NCBI

13 

Tchekmedyian V, Sherman EJ, Dunn L, Tran C, Baxi S, Katabi N, Antonescu CR, Ostrovnaya I, Haque SS, Pfister DG and Ho AL: Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol. 37:1529–1537. 2019. View Article : Google Scholar : PubMed/NCBI

14 

Zhu G, Zhang L, Dou S, Li R, Li J, Ye L, Jiang W, Dong M, Ruan M, Yang W and Zhang C: Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: A single-arm, phase II prospective study. Ther Adv Med Oncol. 13:175883592110136262021. View Article : Google Scholar : PubMed/NCBI

15 

Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A and Levitt M: A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol. 43:33–36. 2007. View Article : Google Scholar : PubMed/NCBI

16 

Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A and Siu LL: Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: A princess margaret hospital phase II consortium study. J Clin Oncol. 23:585–590. 2005. View Article : Google Scholar : PubMed/NCBI

17 

Edwards PC, Bhuiya T and Kelsch RD: C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 95:586–593. 2003. View Article : Google Scholar : PubMed/NCBI

18 

Vered M, Braunstein E and Buchner A: Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck. 24:632–636. 2002. View Article : Google Scholar : PubMed/NCBI

19 

Locati LD, Bossi P, Perrone F, Potepan P, Crippa F, Mariani L, Casieri P, Orsenigo M, Losa M, Bergamini C, et al: Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol. 45:574–578. 2009. View Article : Google Scholar : PubMed/NCBI

20 

Jakob JA, Kies MS, Glisson BS, Kupferman ME, Liu DD, Lee JJ, El-Naggar AK, Gonzalez-Angulo AM and Blumenschein GR Jr: Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck. 37:644–649. 2015. View Article : Google Scholar : PubMed/NCBI

21 

Ho AL, Dunn L, Sherman EJ, Fury MG, Baxi SS, Chandramohan R, Dogan S, Morris LG, Cullen GD, Haque S, et al: A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma. Ann Oncol. 27:1902–1908. 2016. View Article : Google Scholar : PubMed/NCBI

22 

Laurie SA, Ho AL, Fury MG, Sherman E and Pfister DG: Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: A systematic review. Lancet Oncol. 12:815–824. 2011. View Article : Google Scholar : PubMed/NCBI

23 

Locati LD, Galbiati D, Calareso G, Alfieri S, Singer S, Cavalieri S, Bergamini C, Bossi P, Orlandi E, Resteghini C, et al: Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life. Cancer. 126:1888–1894. 2020. View Article : Google Scholar : PubMed/NCBI

24 

Geiger JL, Ismaila N, Beadle B, Caudell JJ, Chau N, Deschler D, Glastonbury C, Kaufman M, Lamarre E, Lau HY, et al: Management of salivary gland malignancy: ASCO guideline. J Clin Oncol. 39:1909–1941. 2021. View Article : Google Scholar : PubMed/NCBI

25 

von Witzleben A, Müller-Richter U, Maurus K, Brändlein S, Theodoraki MN, Brunner C, Laban S, Lennerz J, Möller P, Hoffmann TK, et al: Protein-based oncopanel as addition to target sequencing in head and neck squamous cell carcinoma to individualize treatment decisions. Int J Mol Sci. 23:158352022. View Article : Google Scholar : PubMed/NCBI

26 

Takahashi H, Tada Y, Saotome T, Akazawa K, Ojiri H, Fushimi C, Masubuchi T, Matsuki T, Tani K, Osamura RY, et al: Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol. 37:125–134. 2019. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Thölken R, Von Witzleben A, Laban S, Weissinger SE, Hoffmann TK, Schuler PJ and Doescher J: Feasibility of a targeted protein panel for personalized treatment in advanced adenoid cystic carcinoma: A proof‑of‑concept study . Oncol Lett 33: 4, 2027.
APA
Thölken, R., Von Witzleben, A., Laban, S., Weissinger, S.E., Hoffmann, T.K., Schuler, P.J., & Doescher, J. (2027). Feasibility of a targeted protein panel for personalized treatment in advanced adenoid cystic carcinoma: A proof‑of‑concept study . Oncology Letters, 33, 4. https://doi.org/10.3892/ol.2026.15939
MLA
Thölken, R., Von Witzleben, A., Laban, S., Weissinger, S. E., Hoffmann, T. K., Schuler, P. J., Doescher, J."Feasibility of a targeted protein panel for personalized treatment in advanced adenoid cystic carcinoma: A proof‑of‑concept study ". Oncology Letters 33.1 (2027): 4.
Chicago
Thölken, R., Von Witzleben, A., Laban, S., Weissinger, S. E., Hoffmann, T. K., Schuler, P. J., Doescher, J."Feasibility of a targeted protein panel for personalized treatment in advanced adenoid cystic carcinoma: A proof‑of‑concept study ". Oncology Letters 33, no. 1 (2027): 4. https://doi.org/10.3892/ol.2026.15939
Copy and paste a formatted citation
x
Spandidos Publications style
Thölken R, Von Witzleben A, Laban S, Weissinger SE, Hoffmann TK, Schuler PJ and Doescher J: Feasibility of a targeted protein panel for personalized treatment in advanced adenoid cystic carcinoma: A proof‑of‑concept study . Oncol Lett 33: 4, 2027.
APA
Thölken, R., Von Witzleben, A., Laban, S., Weissinger, S.E., Hoffmann, T.K., Schuler, P.J., & Doescher, J. (2027). Feasibility of a targeted protein panel for personalized treatment in advanced adenoid cystic carcinoma: A proof‑of‑concept study . Oncology Letters, 33, 4. https://doi.org/10.3892/ol.2026.15939
MLA
Thölken, R., Von Witzleben, A., Laban, S., Weissinger, S. E., Hoffmann, T. K., Schuler, P. J., Doescher, J."Feasibility of a targeted protein panel for personalized treatment in advanced adenoid cystic carcinoma: A proof‑of‑concept study ". Oncology Letters 33.1 (2027): 4.
Chicago
Thölken, R., Von Witzleben, A., Laban, S., Weissinger, S. E., Hoffmann, T. K., Schuler, P. J., Doescher, J."Feasibility of a targeted protein panel for personalized treatment in advanced adenoid cystic carcinoma: A proof‑of‑concept study ". Oncology Letters 33, no. 1 (2027): 4. https://doi.org/10.3892/ol.2026.15939
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team